Eli Lilly and Company (NYSE:LLY) Sets New 12-Month High – Here’s What Happened

Eli Lilly and Company (NYSE:LLY)’s stock price hit a new 52-week high on Wednesday . The company traded as high as $1,286.30 and last traded at $1,288.7370, with a volume of 845915 shares traded. The stock had previously closed at $1,225.73.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Obesity portfolio remains the main catalyst. Lilly’s Zepbound sales reportedly increased 46%, while recent coverage indicates its GLP-1 portfolio is outpacing Novo Nordisk’s in the latest quarter. Investors are also watching oral obesity candidates and retatrutide as potential sources of future growth. How Does LLY’s Q2 GLP-1 Portfolio Performance Stack Up Against NVO’s?
• Positive Sentiment: Pipeline activity continues across several therapeutic areas. Lilly advanced early-stage studies involving LY4178256, eloralintide, lepodisiran and oral candidate LY4065967, while completing a Phase 3 lebrikizumab trial in atopic dermatitis. These updates do not provide immediate revenue, but they reinforce the company’s longer-term growth prospects. Lilly’s Lebrikizumab Trial Completion Signals New Growth Path
• Positive Sentiment: Fundamentals remain strong. Lilly’s latest quarterly earnings and revenue substantially exceeded consensus estimates, with revenue rising 47.7% year over year. Analysts continue to cite GLP-1 momentum and a broad pipeline as reasons for a constructive long-term outlook.
• Neutral Sentiment: Lehigh Valley construction plans emphasize traffic mitigation. Lilly outlined measures intended to reduce disruption from construction, an operational update that may ease local execution concerns but is unlikely to materially affect near-term earnings. Eli Lilly Lehigh Valley Construction Plans
• Negative Sentiment: Valuation and competition are weighing on sentiment. With LLY valued above $1 trillion and trading at a high earnings multiple, investors may be taking profits after its recent rally. Novo Nordisk and potential entrants such as Pfizer are intensifying the race for oral and next-generation obesity treatments, raising future pricing and market-share risks. Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race?

Wall Street Analysts Forecast Growth

LLY has been the subject of several research reports. Guggenheim increased their price objective on shares of Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the company a “buy” rating in a report on Monday, July 13th. Bank of America boosted their target price on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. BMO Capital Markets restated an “outperform” rating and set a $1,400.00 price target on shares of Eli Lilly and Company in a report on Thursday, August 6th. Royal Bank Of Canada lifted their price objective on Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 8th. Finally, Wolfe Research reaffirmed an “outperform” rating and set a $1,350.00 price objective on shares of Eli Lilly and Company in a report on Thursday, May 21st. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,292.18.

Eli Lilly and Company Stock Performance

The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The business has a 50 day moving average price of $1,177.74 and a 200 day moving average price of $1,058.43. The stock has a market cap of $1.17 trillion, a P/E ratio of 41.84, a PEG ratio of 1.51 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, beating the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The company had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. During the same quarter in the prior year, the company posted $6.31 EPS. Eli Lilly and Company’s quarterly revenue was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, sell-side analysts expect that Eli Lilly and Company will post 36.35 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is currently 23.22%.

Insider Buying and Selling at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 2,000 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. This represents a 56.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the transaction, the executive vice president directly owned 11,875 shares in the company, valued at approximately $14,131,250. The trade was a 29.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 13,500 shares of company stock valued at $15,958,170. Company insiders own 0.14% of the company’s stock.

Institutional Trading of Eli Lilly and Company

A number of institutional investors have recently made changes to their positions in LLY. Banco de Sabadell S.A grew its position in Eli Lilly and Company by 0.8% during the 2nd quarter. Banco de Sabadell S.A now owns 4,248 shares of the company’s stock worth $5,092,000 after purchasing an additional 34 shares during the last quarter. Independence Bank of Kentucky boosted its position in Eli Lilly and Company by 0.5% in the 2nd quarter. Independence Bank of Kentucky now owns 14,360 shares of the company’s stock worth $17,224,000 after purchasing an additional 67 shares in the last quarter. Vanguard Capital Wealth Advisors boosted its holdings in Eli Lilly and Company by 26.5% during the second quarter. Vanguard Capital Wealth Advisors now owns 735 shares of the company’s stock worth $882,000 after buying an additional 154 shares in the last quarter. Acorn Wealth Advisors LLC increased its holdings in Eli Lilly and Company by 6.7% in the second quarter. Acorn Wealth Advisors LLC now owns 620 shares of the company’s stock valued at $744,000 after buying an additional 39 shares in the last quarter. Finally, Triumph Capital Management raised its position in shares of Eli Lilly and Company by 28.5% in the second quarter. Triumph Capital Management now owns 3,038 shares of the company’s stock worth $3,644,000 after acquiring an additional 673 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.